Nightingale Hospital   Report issue

Academic/Hospital Phase 2
Founded: London United Kingdom

Organization Overview

First Clinical Trial
2012
NCT01484574
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

Florence Nightingale Hospital, Istanbul | Nightingale Health Oy

Active Ingredients

Drugs in Phase 2 Trials (1)

allogeneic adipose derived mesenchymal stem cell (1 trial)

Drugs in Other Trials (1)

vitamin d3 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Ischemia (Phase 2)

Thromboangiitis Obliterans (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 2